EUVIMEDEUVIMED entdecken
Crossref

Crafting a Molecular Trojan Horse: Sialic Acid-Modified PLGA Nanoparticles for Targeted Lung Cancer Therapy

Krishan Kumar, Manjit Saini iD, Varsha Rani, Mohini Mishra, Priya, Jatin, Siddharth Tiwari, Brahmeshwar Mishra iD, Ruchi Chawla iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c00957 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Krishan Kumar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh 221005, Ind…. Hauptthemen laut MEDLINE: Lung Neoplasms, Nanoparticles, N-Acetylneuraminic Acid, Polylactic Acid-Polyglycolic Acid Copolymer. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The glycan receptors prominently expressed on the surface of lung cancer cells offers promising targets for drug delivery. The prepared gemcitabine (GB)-loaded PLGA-NPs and sialic acid (Siac)-modified PLGA-NPs exhibited a uniform polydispersity index (PDI) value below 0.3, a particle size under 200 nm, and negative zeta potentials ranging from -17.45 to -21.45 mV. Entrapment efficiency (% EE) and drug loading values exceeded 70% and 8%, respectively. SEM and TEM showed that the particles were uniformly dispersed with a spherical shape. FTIR, XRD, TGA, and DSC analyses indicated the physiochemical stability of the drug within the nanoformulations. Controlled (26.92 to 31.64% within 24 h at pH 7.4) and pH-sensitive (36.80 to 40.25% within 24 h at pH 5.5) GB release were observed for the different formulations of PLGA-NPs. The MTT cytotoxicity assay revealed IC50 values for the GB control, GB-PLGA-NPs, and GB-PLGA-Siac-NPs as 13.65 ± 1.20, 8.14 ± 1.24, and 4.16 ± 1.05 μg/mL, respectively. The Co6-GB-PLGA-Siac-NPs showed significantly higher cellular uptake than that of the Co6-GB control (p < 0.001) and Co6-GB-PLGA-NPs (p < 0.01) respectively. Pharmacokinetic profiles indicated higher AUC values (ng·h/mL) for GB-PLGA-Siac-NPs (8355.07 ± 2006.45) compared to GB-PLGA-NPs (6145.58 ± 969.25) and the GB control (1510.72 ± 81.08), resulting in higher bioavailability of GB-PLGA-Siac-NPs. Biodistribution studies confirmed superior localization of DiD-GB-PLGA-Siac-NPs, indicated by radiant efficiency signal on B[a]P induced lung cancerous tissues relative to DiD-GB-PLGA-NPs after 1 h (p < 0.001), 4 h (p < 0.01), and 12 h (p < 0.001), which could be attributed to their ability to target glycans. In vivo anticancer efficacy in a B[a]P-induced lung cancer mice model depicted that GB-PLGA-Siac-NPs effectively inhibited lung cancer cells and reduced systemic toxicity, as evidenced by the average number of lung cancer cells, body weight values, survival analysis, biochemical parameters associated with organs (such as the liver and kidney), and histopathological analysis. Therefore, GB-loaded Siac-coated PLGA nanoparticles could serve as an efficient vehicle for GB delivery via targeting glycan receptors in lung cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsNanoparticlesN-Acetylneuraminic AcidPolylactic Acid-Polyglycolic Acid CopolymerDeoxycytidineAnimalsHumansMiceGemcitabineParticle SizeCell Line, TumorDrug CarriersDrug Delivery SystemsDrug LiberationRatsMaleA549 Cells

Stichwörter der Autor:innen

PLGA nanoparticlesdrug deliverygemcitabinelung cancernanomedicinetargeted therapy

Substanzen

N-Acetylneuraminic AcidPolylactic Acid-Polyglycolic Acid CopolymerGemcitabineDeoxycytidineDrug Carriers

Autor:innen und Institutionen

  • Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh 221005, India.
  • Institute of Pharmaceutical Research, GLA University, Mathura 281406, India.
  • Jichi Medical University Shimostuke, Shimotsuke, Tochigi Pefecture 329-0431, Japan.
  • Department of Pharmacy, Barkatullah University, Bhopal, Madhya Pradesh 462026, India.
  • School of Pharmaceutical Sciences, CSJM University, Kanpur, Uttar Pradesh 208024, India.

ORCID-Profile: Manjit Saini, Brahmeshwar Mishra, Ruchi Chawla

Zitieren

APA

Kumar, K., Saini, M., Rani, V., Mishra, M., Priya, Jatin, Tiwari, S., Mishra, B., & Chawla, R. (2025). Crafting a Molecular Trojan Horse: Sialic Acid-Modified PLGA Nanoparticles for Targeted Lung Cancer Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00957

Vancouver

Kumar K, Saini M, Rani V, Mishra M, Priya, Jatin, et al. Crafting a Molecular Trojan Horse: Sialic Acid-Modified PLGA Nanoparticles for Targeted Lung Cancer Therapy. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c00957

BibTeX
@article{Kumar2025,
  author = {Kumar, Krishan and Saini, Manjit and Rani, Varsha and Mishra, Mohini and Priya and Jatin and Tiwari, Siddharth and Mishra, Brahmeshwar and Chawla, Ruchi},
  title = {Crafting a Molecular Trojan Horse: Sialic Acid-Modified PLGA Nanoparticles for Targeted Lung Cancer Therapy},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c00957}
}
Kostenlos starten →